Last 0.63 GBp
Change Today 0.00 / 0.00%
Volume 50.0K
AVCT On Other Exchanges
As of 3:01 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

avacta group plc (AVCT) Snapshot

0.63 GBp
Previous Close
0.63 GBp
Day High
0.63 GBp
Day Low
0.63 GBp
52 Week High
02/14/14 - 1.25 GBp
52 Week Low
11/27/14 - 0.62 GBp
Market Cap
Average Volume 10 Days
-0.0004 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for AVACTA GROUP PLC (AVCT)

Related News

No related news articles were found.

avacta group plc (AVCT) Related Businessweek News

No Related Businessweek News Found

avacta group plc (AVCT) Details

Avacta Group plc researches, develops, produces, and delivers instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology in the United Kingdom and internationally. It operates in three segments; Analytical, Animal Health, and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterization and analysis for biopharmaceutical drug developers. The Animal Health segment offers tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug, and biomarker discovery in biotech research and development. The company offers Optim 2, an analytical instrument designed to probe multiple protein stability-indicating parameters at high speed using ultra-low sample volumes of proteins and other molecules for the measurement of aggregation, unfolding, and stability of microlitre volumes of biopharmaceutical products under different physical, chemical, and formulation conditions. The company is based in Wetherby, the United Kingdom.

avacta group plc (AVCT) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 148.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 84.0K GBP
Compensation as of Fiscal Year 2013.

avacta group plc (AVCT) Key Developments

Avacta Group plc Announces Audited Consolidated Earnings Results for the Year Ended July 31, 2014

Avacta Group Plc announced audited consolidated earnings results for the year ended July 31, 2014. For the year, the company reported operating loss of £2,067,000 against £1,873,000 a year ago. Loss before taxation was £2,043,000 against £1,852,000 a year ago. Loss was £1,492,000 or 0.04 pence per basic and diluted share against £1,521,000 or 0.05 pence per basic and diluted share a year ago. Net cash used in operating activities was £838,000 against £1,377,000 a year ago. Purchase of plant and equipment were £922,000 against £478,000 a year ago. Purchase of intangible assets was £17,000. Adjusted EBITDA loss reduced to £1.10 million compared to £1.46 million a year ago. Adjusted loss before tax reduced to £1.81 million compared to £1.92 million a year ago.

Avacta Group Plc, 2014 Earnings Call, Oct 16, 2014

Avacta Group Plc, 2014 Earnings Call, Oct 16, 2014

Avacta Group plc Announces Appointment of Daniel Gare as Avacta Life Sciences' Business Development Team

Avacta Group plc announced that Dr. Daniel Gare has joined Avacta Life Sciences' business development team effective as of 21st September. Dr. Gare joins Avacta from Abcam plc where he was Head of Strategic Accounts Europe with commercial responsibility for custom products across Europe. Prior to his period of employment at Abcam, Dr. Gare held key roles in Roche Diagnostics UK where he undertook the responsibility for sales of the Translational Diagnostics (TDx) product line in the UK, Ireland and the Nordic countries.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVCT:LN 0.63 GBp 0.00

AVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVACTA GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at